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Maintenance of tissue homeostasis and immune surveillance are important functions of the lymphatic
vascular system. Lymphatic vessels are lined by lymphatic endothelial cells (LECs). By gene micro-array
expression studies we recently compared human lymphangioma-derived LECs with umbilical vein
endothelial cells (HUVECs). Here, we followed up on these studies. Besides well-known LEC markers,
we observed regulation of molecules involved in immune regulation, acetylcholine degradation and
platelet regulation. Moreover we identiﬁed differentially expressed WNT pathway components, which
play important roles in the morphogenesis of various organs, including the blood vascular system. WNT
signaling has not yet been addressed in lymphangiogenesis. We found high expression of FZD3, FZD5 and
DKK2 mRNA in HUVECs, and WNT5A in LECs. The latter was veriﬁed in normal skin-derived LECs. With
immunohistological methods we detected WNT5A in LECs, as well as ROR1, ROR2 and RYK in both LECs
and HUVECs. In the human, mutations of WNT5A or its receptor ROR2 cause the Robinow syndrome.
These patients show multiple developmental defects including the cardio-vascular system. We studied
Wnt5a-knockout (ko) mouse embryos at day 18.5. We show that the number of dermal lymphatic
capillaries is signiﬁcantly lower in Wnt5a-null-mice. However, the mean size of individual lymphatics
and the LEC number per vessel are greater. In sum, the total area covered by lymphatics and the total
number of LECs are not signiﬁcantly altered. The reduced number of lymphatic capillaries indicates a
sprouting defect rather than a proliferation defect in the dermis of Wnt5a-ko-mice, and identiﬁes Wnt5a
as a regulator of lymphangiogenesis.
& 2013 Elsevier Inc. All rights reserved.Introduction
The maintenance of tissue homeostasis is one of the important
functions of the lymphatic vascular system. Developmental defects
like primary lymphedema and lymphangioma lead to functional
disorders with decreased quality of life for patients. Lymphan-
gioma is usually considered as a vascular malformation with foci of
proliferating lymphatic endothelial cells (LECs). Its etiology is
unknown (Filston, 1994; Okazaki et al., 2007; Witte et al., 2001).
Studies of the last years have identiﬁed markers for LECs, e.g., the
hyaluronan receptor Lyve-1, the glycoprotein podoplanin and the
transcription factor Prox1 (Banerji et al., 1999; Breiteneder-Geleff
et al., 1999; Wigle and Oliver, 1999). Therefore, LECs are now well
distinguishable from blood vascular endothelial cells (BECs). The
development of speciﬁc antibodies provided the opportunity to
separate these two types of endothelial cells by ﬂuorescence
activating cell sorting and magnetic cell separation (Hirakawa
et al., 2003; Kriehuber et al., 2001).ll rights reserved.
ment of Anatomy and Cell
ring 36, 37075 Goettingen,
n.de (K. Buttler).In previous studies we characterized LECs from dermal lym-
phangiomas of two children (Norgall et al., 2007). We performed
gene microarray analyses in comparison with human umbilical
vein endothelial cells (HUVECs). Approximately 1200 genes were
regulated in LECs. As expected, the above noted lymphendothelial
markers were highly expressed. We now followed up on these
studies and focused on molecules, which have not yet been
studied in the context of lymphangiogenesis. Among these we
found WNT5A (wingless-type MMTV integration site family,
member 5A), which was regarded as a regulator of angiogenesis.
WNTs belong to a family of secreted glycoproteins that operate via
three pathways with various receptors and co-receptors. They
control fundamental mechanisms during embryonic development
like proliferation, migration and cell fate speciﬁcation (Dale, 1998;
Logan and Nusse, 2004). Dysregulation of WNT signaling pathways
has been observed under pathological conditions, e.g., in cancer,
rheumatoid arthritis and Alzheimer′s disease (De Ferrari and
Inestrosa, 2000; Polakis, 2000; Sen et al., 2000).
In the canonical signaling pathway, WNT proteins bind to
Frizzled (FZD) receptors and form a complex with low density
lipoprotein (LDL) receptor-related protein 5 or 6 (LRP5/6) at the
cell surface. Hence, the intracellular proteins Dishevelled (Dsh)
and Axin become activated with subsequent accumulation of
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involve the transcription factor lymphoid enhancer-binding factor
1/T cell-speciﬁc transcription factor (LEF1/TCF). Lack of WNT
ligands entails the degradation of β-catenin, controlled by the
formation of a complex comprising axin, adenomatous polyposis
coli (APC) and glycogen synthase kinase-3β (GSK3β) (MacDonald
et al., 2009). Additionally, non-canonical Wnt pathways are the
Wnt/calcium (Ca2+) pathway, which activates phospholipase C,
and the planar cell polarity (PCP) pathway, acting through Rho
and Rock (Rho-associated kinase) as well as Rac1 and JNK in a
β-catenin independent manner.
Much of the activity of WNT5A is transduced via non-canonical
pathways and the transmembrane receptors ROR2 (receptor tyr-
osine kinase-like orphan receptor 2), ROR1 and RYK (receptor-like
tyrosine kinase) (Fukuda et al., 2008; Keeble et al., 2006; Mikels
and Nusse, 2006). Thereby, the non-canonical pathways possess
the ability to inhibit the canonical one. This seems to depend on
the availability and activation status of the ligands and receptors,
as well as the involved cell types (Pandur et al., 2002; Seifert and
Mlodzik, 2007; van Amerongen et al., 2008). Recent studies have
proposed essential roles of Wnts in angiogenic processes, e.g.,
vascular morphogenesis, vessel sprouting and elongation (Cirone
et al., 2008). However, Wnts have not been investigated in
lymphangiogenesis so far. Here, we studied lymphatic vessels of
Wnt5a-knockout (ko) mouse embryos in comparison to hetero-
zygous and wild type mice. Immunohistological staining was
performed to characterize the morphology and frequency of
lymphatics in the dermis. Number and shape of lymphatic vessels
of the dermis were affected in Wnt5a-ko-mice. Our studies show a
function for Wnt5a in the development of dermal lymphatic
capillaries.Materials and methods
Animals
Wnt5atm1Amc B6 mice were bought from The Jackson Labora-
tory (Bar Harbor, Maine, USA). Heterozygous animals were bred to
obtain embryos at embryonic day (ED) 12.5 and 18.5. Wild type,
heterozygous and homozygous ko-mice were obtained at near
Mendelian rates. Embryos were genotyped by the application of
multiplex polymerase chain reactions (PCR) with the following
primers: Wild type forward, 5′GAG GAG AAG CGC AGT CAA TC3′;
mutant forward, 5′GCC AGA GGC CAC TTG TGT AG3′ and common
reverse, 5′CAT CTC AAC GGC CTC AT3′. The products possessed
fragment lengths of 400 base pairs (bp) for the mutant allele, and
480 bp for the wild type allele. PCR was performed under standard
conditions and analyzed by ethidium bromide staining of agarose
gels (Supplementary Fig. 1).
Isolation of lymphatic endothelial cells and cell culture
LECs were isolated from lymphangiomas of two male patients,
10 and 4 months of age. Lymphangiomas were located in the
axillary region of patient A, and in the upper arm of patient B. The
studies were approved by the hospital's ethics committee and
were performed with the informed consent of the patient's
parents. Explants of endothelial cells were cultured in Petri dishes
over 4–6 weeks and, using the cell sweeping procedure two times
per week, contaminating stromal cells were removed. This proce-
dure has been described in detail before (Folkman et al., 1979).
Purity of the cultures was controlled by CD31 and Prox1 double
staining, and reached nearly 100% in the studied cultures. Using
standard procedures, human umbilical vein endothelial cells
(HUVECs) were prepared from umbilical cords, with the informedconsent of the parents. Only pure CD31+ cultures were used for
micro-array analyses. LECs and HUVECs were maintained in a
humidiﬁed incubator at 37 1C and 5% CO2 using EBM-2 medium
and supplements (Lonza, Basel, Switzerland). We added 250 ng/ml
human VEGF-C to the LEC culture (ReliaTech, Braunschweig,
Germany). To compare our lymphangioma-derived LECs with LECs
from healthy persons, we used foreskin-derived LECs (PromoCell,
Heidelberg, Germany). The cells were isolated from juvenile fore-
skin and studied in passages 4–5. Cells were cultured in EBM-2
medium with VEGF-C as described above. MDA-MB231 breast
cancer cells were used as positive controls for real-time RT-PCR
experiments. Cells were cultured in RPMI 1640 medium and 10%
FCS (Lonza, Belgium).
RNA micro-array analyses
Here we followed up on micro-array analyses, which were
partially published before (Norgall et al., 2007). Brieﬂy, analyses
were performed at the transcriptome core facility of the UMG
(http://www.microarrays.med.uni-goettingen.de) with 44k whole
genome oligo micro-arrays (Agilent Technologies, Santa Clara, CA,
USA). For hybridization of the probes, a mixture of Cy5 and Cy3
labeled probes was prepared. Per Array 0.7–1.5 mg of Cy-labeled
DNA was used. Hybridization was performed according to the
Agilent ′60-mer oligo micro-array processing protocol. Differen-
tially expressed genes were identiﬁed by ANOVA-procedure. The
resulting raw p-values were adjusted with the Benjamini–Hoch-
berg method to control the false discovery rate.
RNA isolation and real-time RT-PCR
RNA was prepared from freshly harvested cultured cells using
Tri-Reagent solution (Life Technologies, Darmstadt, Germany) and
Omniscript reverse transcriptase kit (Qiagen, Hilden, Germany)
according to the manufacturers recommendation as described
before (Becker et al., 2010). Real time analyses were performed
at least in triplicate on an ABI StepOne-plus device (Life Technol-
ogies) using the Fast SYBR-Green Master Mix (Life Technologies) as
suggested by the manufacturer. The following oligo-nucleotide
primers were used (5′–3′): RYK fwd: agttcgttggatggctcttg, RYK rev:
gagttcccacagcgtcactc; ROR1 fwd: caacaaacggcaaggaggtg, ROR1 rev:
atcctggacttgcagtggga; WNT5A fwd: ctcgccatgaagaagtccat, WNT5A
rev: acattgcacttccagccatc; β-Actin fwd: gcatcccccaagttcacaa,
β-Actin rev: aggactgggccattctcctt. Oligo-nucleotides were synthe-
sized by IBA (Goettingen, Germany). Relative quantiﬁcation was
calculated using the δδCt-method and Microsoft Excel Software.
β-Actin was used as reference gene and lymphangioma LECs
(LEC2) were used as calibrator and set as 1.
Western blot
Cell pellets of HUVECs and LECs were prepared with Laemmli
lysis-buffer (Roth, Karlsruhe, Germany) containing 15% β-
mercaptoethanol and subjected to SDS–PAGE. They were blotted
semi-dry on a nitrocellulose membranes (Amersham Biosciences,
UK). Blocking solution consisting of 5% milk powder in TBS and
0.1% Tween 20 (TBS-T) was used to incubate the blots for one hour.
Primary antibodies against monoclonal rat anti-human Wnt5a
(R&D Systems, #Mab-645, dilution 1:5000), polyclonal rabbit
anti-human ROR1 (Cell Signaling Technology, #4102; dilution
1:3000), monoclonal mouse anti-human ROR2 (provided by A.
Schambony, University Erlangen-Nürnberg, Germany; dilution
1:50) and mouse anti-human α-tubulin (Merck Millipore, #05-
829; dilution 1:5000) dissolved in TBS-T containing bovine
serum albumin (5%) were incubated overnight at 4 1C. After
rinsing in TBS-T, secondary peroxidase-conjugated anti-rabbit
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#2004, #2005, #2006; each diluted 1:6000) were applied for one
hour followed by rinsing in TBS-T. Antibody detection was per-
formed employing ECL prime western blotting detection reagent
(GE Healthcare Europe, Freiburg, Germany). Images were captured
with a luminescence image analyzer (LAS-4000mini, Fujiﬁlm
Europe, Düsseldorf, Germany).
Histology and immunohistology
For parafﬁn histology, ED 18.5 mouse embryos were dissected
and placed overnight in Bouin's ﬁxative. Specimens were
embedded in parafﬁn, sectioned into 8 mm slices and mounted
onto slides. Hematoxylin and eosin (HE) or trichrome staining was
performed. For immunoﬂuorescence staining, ED 12.5 embryos
and tissues from ED 18.5 embryos were ﬁxed in 4% paraformalde-
hyde, rinsed in phosphate-buffered saline (PBS), transferred to 10%
and 30% sucrose in PBS, and embedded in Tissue Freeze Medium
(Sakura Finetek Europe, NL). Cryosections were incubated with
bovine serum albumin (BSA), and stained with rat anti-mouse
CD31/PECAM-1 (1:50; BD Pharmingen, San Diego, USA), rabbit
anti-mouse LYVE-1 (1:100; Regeneron, Tarrytown, NY, USA), rabbit
anti-human Prox1 (1:500; ReliaTech, Braunschweig, Germany),Fig. 1. (A and B) Expression of endothelial/lymphendothelial markers in human LECs
endothelial marker CD31/PECAM-1 (green) in the cell membrane and the transcription fa
but are negative for Prox1. Counterstaining with Dapi (blue). Scale bar in (A) 30 mm. (C) Re
types are: LEC2 (lymphangioma-derived LECs), HUVEC, LEC9 (foreskin-derived LECs),
calibrator and set as 1. (D and E) Immunocytology with anti-WNT5A antibodies (green) s
Scale bar in (E) 30 mm.rabbit anti-human ROR1 (Cell Signaling Technology, #4102) and
mouse anti-human ROR2 (provided by A. Schambony). In negative
controls primary antibodies were omitted. After rinsing, the
secondary Alexa 488-conjugated goat anti-rat IgG, Alexa 594-
conjugated goat anti-mouse IgG and Alexa 594-conjugated goat
anti-rabbit IgG (Molecular Probes, Eugene, USA) were applied
(1:200). Specimens were counterstained with Dapi (1:40,000; Life
Technologies, NY, USA) and subsequently mounted under cover
slips with Fluoromount-G (Southern Biotechnology Associates,
Birmingham, GB). Double staining of human LECs and HUVECs
with anti-CD31 and anti-Prox1 antibodies was performed in
chamber slides as previously (Norgall et al., 2007). A short
(1 min) permeabilization with Triton was implemented after BSA
incubation. Histological analyses were done with Axio Imager.Z1
(Zeiss, Göttingen, Germany). The macroscopic images of the mouse
embryos were made with a Nikon D70 camera.
Quantitative analyses and statistics
Images for quantiﬁcation were coded and evaluated blindly in
microscopic ﬁelds at 200 magniﬁcation (three different animals
for each group; 14 sections per animal; 3–4 ﬁelds per section).
Both wild type and heterozygous ko-embryos were used asand HUVECs. (A) Isolated LECs from lymphangioma patients co-express the pan-
ctor Prox1 (red) in the nucleus. (B) HUVECs show higher CD31/PECAM-1 expression
al-time RT-PCR of human cell lines with probes against WNT5A, ROR1 and RYK. Cell
and breast cancer cell line MDA-MB231 as a positive control. LEC2 were used as
hows higher expression in LECs than in HUVECs. Counterstaining with Dapi (blue).
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ences between these mice. Number of lymphatics, their area and
mean size, and the number of Prox1-positive dermal LECs (total
count app. 2800 cells) were evaluated. For comparisons of the
mean, the unpaired two-tailed t-test, with Welch's correction
where necessary, and the Mann–Whitney-test were used. Statis-
tical analyses were carried out with GraphPad Prism 5 software
(Vers. 5.03; GraphPad Software, Inc., La Jolla, CA). Data are
presented as mean7SEM. Statistical signiﬁcance is indicated in
the ﬁgures by asterisks.
Fluorescence micro-lymphangiography
To study the functionality of the lymphatics we used ED 18.5
mouse embryos and injected 200–300 nl of 2000 kDa FITC-
dextran (Sigma; 8 mg/ml PBS) into the paws of control embryos
and the most distal part of the legs of the homozygous ko-
embryos (n¼12). Embryos were studied with a ﬂuorescence
stereomicroscope (Leica). Images were taken at regular intervals
up to 15 min after injection.Results
RNA-expression of human LECs compared to HUVECs
We have studied the transcriptome of LECs isolated from
lymphangioma tissues in comparison with HUVECs by micro-
array analyses (Agilent 44k whole human genome oligo micro-
arrays). Our investigations reveal regulation of approximately
1200 genes in the LECs. The lymphendothelial character of the
cells was conﬁrmed by the prominent expression of molecules,
which are characteristic for lymphatic endothelium, such as the
transcription factor Prox1 (Wilting et al., 2002). Its expression was
approximately 38-fold higher in LECs than in HUVECs. Double
staining of LECs with anti-CD31/PECAM-1, a pan-endothelial
marker, and anti-Prox1 antibodies exhibited co-expression of both
markers in LECs; CD31 in the cell membrane and Prox1 in the
nucleus (Fig. 1A), whereas HUVECs only showed CD31-positivityFig. 2. (A) Western blot analyses of lysates from lymphangioma-derived LECs and HUVE
and tubulin (loading control; ∼50 kDa). WNT5A is found in LECs, the receptors in both o
skin from ED 18.5 mouse embryos with antibodies against WNT5A (green) and Prox1 (
Scale bar 30 mm.(Fig. 1B). Other molecules also known to be characteristic of LECs
were highly expressed in our two LEC lines, too, like podoplanin
(107-fold), Lyve-1 (5-fold), reelin (41-fold) and macrophage man-
nose receptor (19-fold). We also found molecules that have not
been studied intensively in lymphatics, such as fatty acid binding
protein 4 (FABP4), which was 52-fold higher in LECs. Immunohis-
tochemical studies of multiple human tissues preformed with
‘The Human Protein Atlas’ (http://www.proteinatlas.org/; see
Uhlen et al. (2005)) showed expression of FABP4 in human
lymphatics, whereas FABP5 was found in both lymphatics and
blood vessels (Supplementary Fig. 2A and B). Also, acetylcholines-
terase (AChE), which has been found in the cell membrane of
HUVECs (Carvalho et al., 2005) was 5.6-fold higher in LECs, and
was expressed in both BECs and LECs (Supplementary Fig. 2C).
In one of the two LEC lines we found 17-fold increased expression
of LGALS3BP (lectin, galactoside-binding, soluble, 3 binding pro-
tein¼MAC2BP), which binds the macrophage associated lectin
LGALS3 (Koths et al., 1993). We observed protein expression of
LGALS3BP in human lymphatics (Supplementary Fig. 2D). In
contrast, in HUVECs we found the highest (240-fold) expression
for ENTPD1 (Ectonucleoside triphosphate diphosphorylase 1,
CD39), an inhibitor of platelet activation (Enjyoji et al., 1999),
and observed immunopositivity in human blood vessels, but not in
lymphatics (Supplementary Fig. 2E). These data show that our
micro-array analyses produced reliable results.
We then focused on the members of the WNT signaling path-
way. WNT5A showed a signiﬁcant 16-fold higher expression in the
two lymphangioma-derived LEC lines than in HUVECs, whereas
other family members (WNT1, WNT6, WNT7a, WNT7b, WNT8b,
WNT11) were almost equally expressed. To study if the high
WNT5A levels in our LECs might be pathological, we compared
them to normal foreskin-derived LECs with qRT-PCR. The normal
LECs showed an even higher value (22% more) than the lymphan-
gioma LECs (Fig. 1C). The different WNT5A expression levels of
LECs and HUVECs were also evident in immunocytological ana-
lyses (Fig. 1D and E).
In the micro-array analyses, the receptors of the WNT signaling
pathway ROR1, ROR2, RYK and LRP5/6 displayed no signiﬁcant
differences between LECs and HUVECs, whereas FZD3 and FZD5Cs with antibodies against WNT5A (∼42 kDa), ROR1 (∼135 kDa), ROR2 (∼135 kDa),
f the cell lines. Positions of size markers are indicated. (B) Immunohistology of the
red) shows expression of WNT5a in lymphatics. Counterstaining with Dapi (blue).
Fig. 3. Immunostaining of adult mouse dermis with: (A) anti-CD31 and (B) anti-Ror2 antibodies. (C) Merged picture. Ror2 is expressed in blood vessels (arrows) and in
vessels that appear to be lymphatics (arrowhead). Scale bar in (C) 25 mm. Staining with (D) lymphendothelial marker anti-podoplanin and (E) anti-Ror2 antibodies. (F)
Merged picture. Ror2 is expressed in lymphatic vessels (arrowhead), and in adjacent hair follicles. Scale bar in (F) 20 mm.
Fig. 4. Immunohistochemical staining of human tissues. Taken from 〈www.proteinatlas.org〉. (A and B) Antibodies against ROR2 show staining of blood vascular and
lymphatic (L) endothelium in (A) small intestine (female 56 years, pat id 3343) and (B) skin (male 83 years, pat id 2156). (C) Antibodies against RYK show staining of blood
vascular and lymphatic (L) endothelium in colon (female 62 years, pat id 3753). Scale bar in (C) 25 mm.
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equal expression of ROR2 (not shown) and RYK, while ROR1 was
considerably higher in HUVECs (Fig. 1C). Correspondingly, in
western blot analyses we found WNT5A in LECs but hardly any
in HUVECs, while both cell lines expressed ROR1 and ROR2
(Fig. 2A). We used these antibodies in human foreskin and in the
dermis of mice. In the dermis of ED 18.5 mouse embryos we found
expression of Wnt5a in lymphatics (Fig. 2B). We could not detect
any signals for Ror1 in the vasculature, but found Ror2 in CD31-
positive vessels of the mouse dermis (Fig. 3A–C). Since CD31 is
expressed in both blood vessels and lymphatics, we applied the
LEC marker podoplanin and observed its colocalization with Ror2
in lymphatics (Fig. 3D–F).
Since our antibodies did not reveal staining of human foreskin,
we used ‘The Human Protein Atlas’ (http://www.proteinatlas.org/;
see Uhlen et al. (2005)). We observed ROR2 signals in the
endothelium of numerous fetal and adult tissues. Thereby both
blood vessels and lymphatics were positive in various organs
(Fig. 4A and B). The WNT5A co-receptor RYK was also found in
both types of vessels (Fig. 4C). Additionally, in human dermis FZD3
was expressed in blood vessel endothelium, but hardly in lym-
phatics (Supplementary Fig. 3A). In our gene micro-array analyses
the WNT modulator Dickkopf homologue 2 (DKK2) was signiﬁ-
cantly higher (6-fold) in HUVECs, and we observed immunostain-
ing with anti-DKK2 in blood vessels of the human placenta and in
various organs (Supplementary Fig. 3B and C) [Fig. 4A–C andSupplementary Fig. 3A–C were photographed from http://www.
proteinatlas.org/].
The inactivation of Wnt2, Wnt5a, Fzd4, Fzd5, Wnt7a+Wnt7b
each induces blood vascular defects (Dejana, 2010). By now,
functions of Wnt signaling have not been studied in lymphangio-
genesis. Since we observed expression of WNT5A in human and
murine LECs and found its receptors ROR1, ROR2 and RYK in
cultured LECs and in the lymphatics of various organs, we studied
the development of lymphatics in Wnt5a-ko-mice.
Morphology of Wnt5a-knockout-mice
Homozygous Wnt5a-ko-mice die postnatally. Therefore, we
investigated the lymphatic network at embryonic day (ED) 18.5.
(Preliminary studies at ED 12.5 did not show obvious differences of
the jugular lymph sacs and we therefore concentrated on the later
stages). Macroscopically, heterozygous ko-embryos appeared nor-
mal, whereas homozygous ko-embryos exhibited several defects
such as a reduced body length, shortening of the mandible,
head, limbs and tail (Fig. 5A), as shown before (Yamaguchi et al.,
1999). Both small and large intestine of the ko-mice showed a
severe reduction in size (Supplementary Fig. 4A), which has
recently been attributed to a massive decrease of enterocyte
proliferation (Cervantes et al., 2009). Despite this massive dyspla-
sia there were no signs of intestinal edema, and anti-Lyve1
staining of the intestinal lymphatics did not show any obvious
Fig. 5. Wnt5a heterozygous and homozygous ko-mice at embryonic day (ED) 18.5. (A) Lateral view shows massive defects of the homozygous ko-animal (right) such as
reduced body length, shortening of the mandible, head, limbs and tail. Heterozygous embryo exhibits normal phenotype (left). (B and C) The skin of the ko-mouse seems to
be modiﬁed and indicates a deep transversal crease in the abdominal skin (arrow). Scale bar 500 mm.
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mentary Fig. 4B and C). During the macroscopic evaluation of the
ED 18.5 embryos, the skin attracted our attention. Whereas the
overall size of the homozygous ko-embryos and the anlagen of
several organs were severely reduced, the skin appeared to be too
large for the embryos, and there existed a deep transversal crease
in the abdominal skin (Fig. 5B and C).
Morphology and lymphatics of the skin
We isolated skin from the dorsal thoracic region and specimens
from the abdominal body wall (consisting of skin, abdominalmuscle and peritoneum). The latter were stained with trichrome
to investigate the microscopic structure. The wild type and
heterozygous animals showed a regular arrangement of epidermis
and dermis, abdominal muscle with an outer and an inner fascia,
and peritoneum. Typically, in the dermis a dermal muscle was
found (Fig. 6A and B). This morphology was severely altered in the
homozygous ko-mice. The connective tissue compartment was
less well organized, showed no signs of fascia development, and
appeared to be increased in size mainly on the expense of the
abdominal muscles, which showed signs of degeneration (Fig. 6C
and D). In control embryos, a regular arrangement of abdominal
skeletal muscles was present, as well as a layer of dermal muscle
Fig. 6. Trichrome staining of the abdominal body wall of ED 18.5 mice. (A) Wild-type embryos possess a regular arrangement of epidermis and dermis with dermal muscle
(dm), abdominal muscles (am), outer fascia (of) and inner fascia (if). (B) Higher magniﬁcation of the boxed area in (A) showing a dense plexus of vessels immediately
underneath the epidermis (arrows in (A) and (B)). (C) In Wnt5a-null-mice the structure of the body wall is altered. The dermal muscle (dm) appears to be normal, but there
are massive signs of degeneration of the abdominal muscles (am). (D) Higher magniﬁcation of the boxed area in (C). Dermal vessels are sparse, but vessels with a large lumen
(arrowhead in (C) and (D)) are seen in the dermis underneath the dermal muscle (dm). Scale bar in (C) 20 mm, (D) 10 mm.
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oped in the homozygous ko-mice, whereas the abdominal muscles
showed signs of degeneration (Fig. 6C and D). Immediately under-
neath the epidermis, above the dermal muscle, a well-developed
vascular plexus was seen in control embryos. This was largely
absent in the Wnt5a-ko-mice, and we observed vessels with a
large lumen in the deeper parts of the dermis, below the dermal
muscle (Fig. 6C and D).
In order to identify lymphatic networks we performed immu-
nohistological staining of dermis, taken from the dorsal thoracic
region and the abdominal region of ED 18.5 mice, with LEC-
speciﬁc antibodies. Using antibodies against CD31 and Lyve-1,
we detected a regular pattern of small lymphatic capillaries in the
thoracic skin of control mice (Fig. 7A–C). In contrast, homozygous
ko-mice possessed lymphatics with a large lumen, which became
evident by staining with CD31 and Lyve-1 (Fig. 7D–F), as well as
CD31 and Prox1 (Fig. 7G). In the abdominal dermis, identical
morphological alterations were evident. Small initial Lyve1+ lym-
phatics were found at regular intervals in the dermis of wild type
and heterozygous ko-mice (Fig. 8A). In contrast, homozygous ko-
mice possessed larger lymphatic vessels located more deeply in
the dermis (Fig. 8B). Blood vessels were Lyve-1-negative, but
expressed CD31/PECAM-1 more strongly than the lymphatics.
We obtained the same results with antibodies against Prox1 and
CD31. Lymphatics co-expressed the two markers. Again, numerous
small lymphatics were found in the dermis of control mice, while
fewer but larger lymphatics were seen in Wnt5a-null-mice (Fig. 8C
and D). There obviously is a generalized defect in the development
of dermal lymphatic capillary networks in Wnt5a-ko-mice.
Quantitative analyses of dermal lymphatics
The immunostaining of the dermal lymphatics allowed us to
quantify their number and size, as well as the number of Prox1/
CD31-positive LECs. Since heterozygous-ko mice showed noquantitative differences to wild type mice, we combined both
genotypes into one control group. We found that the number of
dermal lymphatics was signiﬁcantly (po0.05) reduced in Wnt5a-
ko-mice compared to control mice (Fig. 9A). However, the area of
lymphatics in the dermis did not differ between the two groups
(Fig. 9B), suggesting major alterations of the size of individual
lymphatics in Wnt5a-ko-embryos. In fact, our data reveal a
signiﬁcant increase (po0.0001) in the mean size of the dermal
lymphatics in these mice (Fig. 9C). We also counted the Prox1/
CD31+ LECs to study whether the reduced number of lymphatics
in the Wnt5a-null-mice might be due to a proliferation defect.
Interestingly, the number of LECs did not discriminate between
the two groups, whereas the mean number of endothelial cells per
lymphatic vessel was signiﬁcantly (po0.0001) higher in Wnt5a-
ko-embryos (Fig. 9D and E). The data show that despite a nearly
normal number of dermal LECs, the number of lymphatics
was signiﬁcantly lower in Wnt5a-ko-mice, suggesting a defect in
sprouting.Function of dermal lymphatics
To study the function of dermal lymphatics we injected
2000 kDa FITC-dextran into the paws of the ED 18.5 embryos. This
FITC-dextran is taken up by the lymphatics and transported
centripetally (Hirashima et al., 2008). Since the homozygous
ko-embryos do not develop paws (see Fig. 5), we injected the
marker into the most distal part of the legs. In both wild-type and
heterozygous ko-embryos we observed an immediate uptake of
the marker into the local lymphatic network and the transport
within lymphatic collectors, which are located adjacent to the
main blood vessels of the limbs (Fig. 10A and B). In Wnt5a-null
embryos the uptake of FITC-dextran into the lymphatic capillaries
was greatly delayed and transport in lymphatic collectors was not
observed (Fig. 10C). This shows that both the uptake of interstitial
Fig. 7. Immunostaining of dermal lymphatics in the dorsal thoracic region of ED 18.5 wild-type vs. Wnt5a-ko-mice. Counterstaining of nuclei with Dapi (blue). (A–C)
Expression of CD31 (green) and Lyve-1 (red). (A) Merged picture. In wild-type embryos numerous small lymphatics of the dermis (arrows) co-express CD31 and Lyve-1.
(B) CD31, (C) Lyve-1. Scale bar in (A) 30 mm. (D–F) Huge but irregularly distributed lymphatics in homozygous ko-mice also express CD31 and Lyve-1 (arrows). Scale bar in
(D) 40 mm. (G) Staining with antibodies against CD31 (green) and Prox1 (red). Note lymphatics (arrows) with large lumen. Scale bar 45 mm.
Fig. 8. Immunostaining of dermal lymphatics in the abdominal region of ED 18.5 Wnt5a-ko-mice and controls. (A and B) Expression of CD31 (green) and Lyve-1 (red). (A) In
heterozygous embryos numerous small lymphatics of the dermis (arrows) co-express CD31 and Lyve-1. (B) Lymphatics (arrow) of homozygous ko-mice are considerably
larger, but fewer, and located more deeply in the dermis. Nuclear staining with Dapi (blue). Scale bar in (A) 50 mm. (C and D) Staining with antibodies against CD31 (green)
and Prox1 (red) (C) Heterozygous embryos possess a regular pattern of initial lymphatics (arrows) in the dermis, with co-expression of CD31 in the cell membrane and Prox1
in the nucleus. (D) The huge but irregularly distributed lymphatics in homozygous ko-mice also express both markers (arrows). Counterstaining of nuclei with Dapi (blue). Ep
—epidermis; Scale bar in (C) 50 mm.
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Fig. 9. Quantitative analyses of number, area and mean size of dermal lymphatics, and the number of Prox1-positive dermal LECs in ED 18.5 embryos. (A) The number of
lymphatics per microscopic ﬁeld (200 magniﬁcation) is signiﬁcantly lower in Wnt5a-null-embryos compared to controls. (B) The areas covered by lymphatics do not differ
signiﬁcantly. (C) The mean size of individual dermal lymphatics is signiﬁcantly larger in Wnt5a-ko-mice. (D) There is no statistically signiﬁcant difference in the total number
of Prox1-positive dermal LECs per microscopic ﬁeld (200 magniﬁcation). (E) The mean number of Prox1-positive LECs per vessel is signiﬁcantly higher in Wnt5a-ko-mice.
Results represent means7SEM; *po0.05; **po0.01; ***po0.001.
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embryos.Discussion
Characteristics of the transcriptome of human BECs and LECs
We have isolated and puriﬁed LECs from the dermis of two
lymphangioma patients (Norgall et al., 2007) and compared their
transcriptome with that of freshly isolated HUVECs. One has to be
aware that molecular differences have been observed between
in vitro and ex vivo endothelial cells (Amatschek et al., 2007; Wick
et al., 2007). Nevertheless, in LECs we found high expression of
genes that are well-known LEC markers, such as vascular endothe-
lial growth factor receptor (VEGFR)-3, Prox1, podoplanin, reelin
and Lyve-1 (Hirakawa et al., 2003; Kriehuber et al., 2001; Norgall
et al., 2007; Becker et al., 2012; Podgrabinska et al., 2002; Wilting
et al., 2000), suggesting that our micro-array data are reliable. This
is further supported by the fact that we found many of the
transcriptionally regulated genes expressed as proteins (www.
proteinatlas.org) in BECs or LECs; e.g., fatty acid binding protein
4 (FABP4), acetylcholinesterase (AChE), LGALS3BP (lectin, galacto-
side-binding, soluble, 3 binding protein¼MAC2BP), Ectonucleo-
side triphosphate diphosphorylase 1 (ENTPD1, CD39).
FABP4 is found with high speciﬁcity in LECs. It is a small
cytoplasmic protein that controls metabolic and inﬂammatory
pathways (Furuhashi et al., 2007). Under speciﬁc diet, the total
weight gain in FABP4 / mice is higher than that in wild type
controls (Hotamisligil et al., 1996). AChE is a very rapid enzyme
that hydrolyzes the neurotransmitter acetylcholine. Outside the
nervous system, AChE has been found in the cell membrane of
HUVECs (Carvalho et al., 2005). The expression in HUVECs is
conﬁrmed by our studies, however, we observed even higher
levels in LECs. The functions of AChE in LECs remain to be studied,
however, the close spatial relation between peripheral nerves andthe lymphatics, as well as the fact that high systemic AChE levels
are toxic, may provide an explanation for this ﬁnding.
We found high expression of LGALS3BP in LECs. LGALS3BP is a
90 kDa protein most highly expressed in the gastrointestinal tract
and up-regulated in the serum of patients with AIDS (Ullrich et al.,
1994). The stimulatory effect of LGALS3BP on natural killer cells
and lymphokine-activated killer cells (Ullrich et al., 1994) implies
an active role for LECs in the immune defense. The reliability of our
transcriptome analyses is also supported by the ﬁnding of
ENTPD1/CD39 in HUVECs but not in LECs. CD39 is an inhibitor of
platelet activation (Enjyoji et al., 1999). It hydrolyzes extracellular
ATP and ADP to AMP, which is further converted to adenosine by
the enzyme 5′-nucleotidase. ADP is a powerful agonist for platelet
recruitment and adhesion, and becomes immediately degraded by
CD39 in BECs. On the other hand, adenosine is a potent antagonist
of platelet activation (Kaarbo et al., 2003) and is produced by
5′-nucleotidase, which, notably, was the ﬁrst speciﬁc marker
identiﬁed for LECs (Ji and Kato, 2001). Together, these data show
that both BECs and LECs can inhibit platelet activation, although
with different enzymes. This may explain why lympho-venous
anastomoses, which are produced surgically for the treatment of
lymphedema patients, can be functionally active for a long time
(Ingianni, 2003).
During our further analyses we then focused on the members
of the WNT-signaling pathway, because several of the family
members play crucial roles in hemangiogenesis (Dejana, 2010),
but have not been studied during lymphangiogenesis.
Wnt signaling in hemangiogenesis and lymphangiogenesis
Our micro-array analyses provided evidence for a signiﬁcantly
higher expression of FZD3, FZD5 and DKK2 in HUVECs, while we
detected a 16-fold higher value for WNT5A in lymphangioma-
derived LECs. We detected even higher levels of WNT5A in normal
foreskin-derived LECs. As regards the expression of the receptors
ROR1 and RYK we found equal values in normal and lymphangioma
Fig. 10. Fluorescence micro-lymphangiography of ED 18.5 embryos. Injection of
FITC-dextran into the paw of the hind limb. (A) Transport of the marker in
lymphatic collectors after 2 min in wild-type mice. (B) Transport of the marker in
lymphatic collectors after 2 min in heterozygous ko-mice. (C) No transport in
lymphatic collectors is visible in Wnt5a-null mice after 10 min. There is some
uptake of the marker in proximal lymphatic networks.
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lymphatics and in cultured human LECs, but not in HUVECs. The
WNT5A receptors ROR2 and RYK were found on both blood vessels
and lymphatics.WNT5A is a secreted glycoprotein and a member of a family of
19 ligands binding at least 10 Frizzled receptors and several co-
receptors. WNTs are highly conserved and essential in develop-
mental processes like proliferation, migration, differentiation and
apoptosis (Logan and Nusse, 2004). These are also important steps
in the formation and maintenance of the vascular system (Dejana,
2010). In vitro, the expression of WNTs has been demonstrated in
primary BECs of human and mouse origin (Goodwin et al., 2006;
Wright et al., 1999). These investigation identiﬁed mRNA of nearly
all WNTs (except for WNT1, 3A, 7B, 8B, 16) as well as their
receptors and co-receptors in HUVECs, human microvascular
endothelial cells (which are a mixture of BECs and LECs), and
human/mouse aortic smooth muscle cells. In vivo, expression has
been shown in the embryonic yolk sac (Wnt5a, Wnt10b) and in
fetal vessels of the mouse placenta (Wnt2) (Ishikawa et al., 2001;
Monkley et al., 1996). Wnt2-null-mice have an abnormal placental
vasculature with a reduced number of blood capillaries (Monkley
et al., 1996).
WNT5A and its receptors in angiogenesis and lymphangiogenesis
Our studies have shown a signiﬁcant effect of Wnt5a on dermal
lymphatics. Macroscopically the dermis of ED 18.5 mice appears
oversized, obviously due to increased connective tissue spaces and
altered vascularization. Other organs did not reveal this kind of
dysplasia, showing heterogeneity of Wnt5a-functions in different
organ systems. Such heterogeneity has also been found in terms of
hemangiogenesis, where data on Wnt5a are highly divers and
obviously context dependant. Transfection of WNT5A into HUVECs
has not revealed any proliferative effects or increased stimulation
of β-catenin/TCF activity in these cells, whereas Wnt1 raised cell
proliferation, stabilization of β-catenin and transcription of repor-
ter genes (Wright et al., 1999). However, other studies have
reported that WNT5A induces proliferation of HUVECs and
HDMECs (Cheng et al., 2008; Masckauchan et al., 2006), but
reduces the proliferation of aortic ECs (Goodwin et al., 2007). Still
others have not observed any effects of WNT5A on angiogenesis e.
g., in squamous cell carcinoma (Huang et al., 2005). Our studies
show signiﬁcantly higher expression of WNT5A in dermal
lymphangioma-derived and foreskin LECs as compared to HUVECs.
Accordingly, we found maldevelopment of dermal lymphatics in
Wnt5a-ko-mice. We studied these mice at ED 18.5 because they
die postnatally due to hypoplasia of multiple organ systems
(Yamaguchi et al., 1999).
In contrast to the hypoplasia of multiple organ systems, the
skin of Wnt5a-null mouse embryos appeared oversized. In the
abdominal body wall we observed maldevelopment of various
tissues, e.g., disaggregation of the abdominal skeletal muscle and
the absence of the inner and outer muscular fascia. These spaces
were ﬁlled with loose connective tissue. Hyperplasia of adipose
and connective tissue is a typical sequela of lymphedema patients
(Witte et al., 2001), but we must consider that multiple tissue
alterations take place simultaneously in Wnt5a-null mice. The
reasons for the muscular degeneration are not clear. Cell autono-
mous effects are possible, since Wnt5a has been shown to increase
satellite cell proliferation in adult myogenesis (Otto et al., 2008).
The vascular pattern in the dermis of Wnt5a-ko-mice is
severely altered. Instead of the dense plexus of subepidermal
vessels, there are dilated vessels in deeper positions (below the
dermal muscle) of the skin. The number of initial lymphatics in the
dermis is signiﬁcantly reduced in Wnt5a-null-mice. In contrast,
the area covered by lymphatics is the same as in control embryos,
due to an increased mean diameter of individual vessels. The total
number of LECs, as measured by Prox1/CD31 double staining, is
nearly the same as in the control embryos. This shows that Wnt5a
regulates the morphogenesis of dermal lymphatics, and does not
K. Buttler et al. / Developmental Biology 381 (2013) 365–376 375seem to have signiﬁcant effects on the proliferation of dermal
LECs. There obviously is defective sprouting of dermal lymphatics
in Wnt5a-null-mice resulting in fewer but larger vessels with
more LECs per vessel. The functionality of the initial lymphatics is
greatly reduced, as shown by the delay of FITC-dextran uptake and
the absence of centrifugal transport. We cannot yet comment on
the existence of lymphatic collectors in the Wnt5a-ko-mice. Of
note, canonical Wnt-signaling via β-catenin enhances the expres-
sion of the transcription factor Foxc2 in a model of skeletal muscle
development (Savage et al., 2010). FOXC2 regulates the differentia-
tion of lymphatic collectors and valves, and its loss-of-function
mutations cause lymphedema–distichiasis (Fang et al., 2000). The
existence of quadruple FOX-binding sites in the highly conserved
intron 1 of the WNT5A gene (Katoh, 2009) may indicate a
functional loop.
Robinow syndrome
The Wnt5a-ko-mice recapitulate many features characteristic
for the Robinow syndrome. This is caused by autosomal-recessive
or compound-heterozygous mutations of the ROR2 gene, or by
autosomal-dominant heterozygous mutations of the WNT5A gene
(Person et al., 2010; van Bokhoven et al., 2000). Robinow patients
possess abnormal morphogenesis of the face and external genita-
lia, along with short-limbed dwarﬁsm and vertebral segmentation
anomalies. Additionally, pulmonary atresia with ventricular septal
defects have been observed (Webber et al., 1990). Yet, there are no
reports on the structure and function of the lymphatic vascular
system in the affected patients, and they do obviously not suffer
from generalized edema. However, considering the massively
thickened dermis of the forearm of numerous affected infants
(see 〈http://www.robinow.org/〉) it appears possible that there
is a localized failure of lymph ﬂow in this region. Therefore, our
data obtained in mice may hold true for the human.Acknowledgments
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